Advancements and challenges in personalized neoantigen-based cancer vaccines
Oncology Reviews · 14.03.2025 · 19
DOI: 10.3389/or.2025.1541326 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Oncology Reviews, online erschienen am 14.03.2025. Verfasst von Parminder Singh und 20 weiteren Autor:innen. Beteiligte Einrichtung: Center for Global Health Research, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences, Saveetha University, …. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Advancements in personalized neoantigen-based cancer vaccines are ushering in a new era in oncology, targeting unique genetic alterations within tumors to enhance treatment precision and efficacy. Neoantigens, specific to cancer cells and absent in normal tissues, are at the heart of these vaccines, promising to direct the immune system specifically against the tumor, thereby maximizing therapeutic efficacy while minimizing side effects. The identification of neoantigens through genomic and proteomic technologies is central to developing these vaccines, allowing for the precise mapping of a tumor’s mutational landscape. Despite advancements, accurately predicting which neoantigens will elicit strong immune responses remains challenging due to tumor variability and the complexity of immune system interactions. This necessitates further refinement of bioinformatics tools and predictive models. Moreover, the efficacy of these vaccines heavily depends on innovative delivery methods that enhance neoantigen presentation to the immune system. Techniques like encapsulating neoantigens in lipid nanoparticles and using viral vectors are critical for improving vaccine stability and delivery. Additionally, these vaccines contribute towards achieving Sustainable Development Goal 3.8, promoting universal health coverage by advancing access to safe and effective cancer treatments. This review delves into the potential of neoantigen-based vaccines to transform cancer treatment, examining both revolutionary advancements and the ongoing challenges they face.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Global Health Research, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, India.
- Faculty of Data Science and Information Technology, INTI International University, Nilai, Malaysia.
- Division of Evidence Synthesis, Global Consortium of Public Health and Research, Datta Meghe Institute of Higher Education, Wardha, India.
- Department of Chemistry and Biochemistry, School of Sciences, JAIN (Deemed to be University), Bangalore, Karnataka, India.
- Department of Allied Healthcare and Sciences, Vivekananda Global University, Jaipur, Rajasthan, India.
- Department of Endocrinology, NIMS University, Jaipur, India.
Zitieren
APA
Singh, P., Khatib, M. N., R, R., Kaur, M., Srivastava, M., Barwal, A., Rajput, G. V. S., Rajput, P., Syed, R., Sharma, G., Kumar, S., Shabil, M., Pandey, S., Brar, M., Bushi, G., Mehta, R., Sah, S., Goh, K. W., Satapathy, P., …, & Samal, S. K. (2025). Advancements and challenges in personalized neoantigen-based cancer vaccines. Oncology Reviews, 19. https://doi.org/10.3389/or.2025.1541326
Vancouver
Singh P, Khatib MN, R R, Kaur M, Srivastava M, Barwal A, et al. Advancements and challenges in personalized neoantigen-based cancer vaccines. Oncology Reviews. 2025;19. doi:10.3389/or.2025.1541326
BibTeX
@article{Singh2025,
author = {Singh, Parminder and Khatib, Mahalaqua Nazli and R, Roopashree and Kaur, Mandeep and Srivastava, Manish and Barwal, Amit and Rajput, G V Siva and Rajput, Pranchal and Syed, Rukshar and Sharma, Gajendra and Kumar, Sunil and Shabil, Muhammed and Pandey, Sakshi and Brar, Manvinder and Bushi, Ganesh and Mehta, Rachana and Sah, Sanjit and Goh, Khang Wen and Satapathy, Prakasini and Gaidhane, Abhay M and Samal, Shailesh Kumar},
title = {Advancements and challenges in personalized neoantigen-based cancer vaccines},
journal = {Oncology Reviews},
year = {2025},
volume = {19},
doi = {10.3389/or.2025.1541326}
}
EUVIMED